New application of malaria erythrocytic stage inactivated whole organism vaccine

A technology of erythrocyst and vaccine, which is applied in the field of inactivated whole worm vaccine during erythrocyst, can solve the problems that affect popularization and application, unacceptable, short activity maintenance time, etc., and achieve the effect of expanding the scope of use and preventing mutual transmission

Inactive Publication Date: 2015-07-15
ARMY MEDICAL UNIV
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, in general, the immunogenicity of the transmission-blocking antigen is weak and the activity maintenance time is short, and some immune adjuvants also limit their application due to safety hazards.
Although the poxvirus vector system and yeast expression system have improved many deficiencies in the prokaryotic expression of transmission blocking antigens, the recombinant protein cannot be refolded to its natural conformation, resulting in low affinity of the produced antibodies to pathogens
In addition, existing malaria transmission-blocking vaccines also face problems such as low levels of induced antibodies and adverse reactions caused by immune adjuvants
More importantly, since the transmission-blocking vaccine cannot protect the immunized, it is not easy to be accepted by the population, which seriously affects its promotion and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of malaria erythrocytic stage inactivated whole organism vaccine
  • New application of malaria erythrocytic stage inactivated whole organism vaccine
  • New application of malaria erythrocytic stage inactivated whole organism vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Preparation of embodiment 1 inactivated whole worm vaccine

[0022] First resuscitate the Plasmodium NSM strains preserved in liquid nitrogen, then infect 8-10 Balb / c mice with the resuscitated NSM, and collect NSM parasites as parasite antigens on the 4th day and the 9th day after infection, respectively. The main process of the parasite antigen acquisition process is as follows: the blood components of the mouse are obtained by taking blood from the heart, and added to a centrifuge tube containing heparin to avoid coagulation; the above blood cells are washed 3 times with PBS with a pH value of 7.4 and a concentration of 0.1mol / L After heparin was removed, saponin with a final concentration of 0.5% was added to lyse red blood cells to release intracellular parasite antigens; the above components were washed with PBS three times to remove heme, and the protozoan cells were lysed by repeated freezing and thawing to obtain available Antigens for experiments; resuspend th...

Embodiment 2

[0024] Example 2 The protective effect of whole worm immune serum on erythrocyst

[0025] Resuscitate Plasmodium strain NSM stored in liquid nitrogen, press 1×10 6 The amount of protozoa / only infects 3 Balb / c mice after 3 times of immunizations in embodiment 1, and is compared with 3 normal Babl / c mice; Interval 24h gets tail tip blood and makes blood smear and counts protozoan blood disease. See the experimental results figure 1 , where M1-M3 are control mice, and M4-M6 are whole worm immunized mice. Depend on figure 1 It can be seen that Balb / c mice immunized with whole worms obtained a good protective effect against large doses of Plasmodium erythroplasma infection: the maximum parasite rate of immunized mice was reduced by more than 75%, and the clearance time of protozoa was shortened to 7 days. The vaccine contains all the antigens of the red inner stage of Plasmodium, so it can induce the host's immune system to produce a stronger immune response.

Embodiment 3

[0026] Example 3 Inactivated whole worm vaccine blocks mosquito transmission

[0027] First infect Anopheles mosquitoes with Plasmodium: Resuscitate NSM of Plasmodium strains preserved in liquid nitrogen at 1 x 10 6 6 Balb / c mice were infected at the rate of one per mouse, and the blood smear was used to evaluate the gametocytes of Plasmodium 4 days later, and the mice with the same gametocytes were selected for subsequent experiments.

[0028] Observing the effect of inactivated holozoa vaccine immune serum in mosquito transmission blockage by adoptive holozoa immune serum; the specific IgG antibody in holozoa immune serum was obtained by protein-a protein affinity chromatography gel separation, Observing the role of specific antibodies in mosquito transmission blockage by IgG adoptive method (Table 1); injecting anti-CD4+T cell antibodies into mice to antagonize and inhibit the production of CD4+T cells to interferon (IFN-γ) In the way of mainly inflammatory factors, the ro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a new application of a malaria erythrocytic stage inactivated whole organism vaccine, and in particular relates to an application of the malaria erythrocytic stage inactivated whole organism vaccine serving as a transmission blocking type vaccine. According to the new application disclosed by the invention, a plasmodium erythrocytic stage immune serum is applied to a plasmodium mosquito stage transmission stage, and a whole organism vaccine used at the erythrocytic stage is discovered to show a certain effect of blocking mosquito stage transmission, so that the application range of the whole organism vaccine is enlarged, the preventing and curing effects on an immune individual are achieved, and the transmission opportunity of malaria among groups can be greatly reduced.

Description

technical field [0001] The invention relates to a vaccine, in particular to a new use of an inactivated erythrocystis vaccine for preventing and treating malaria. Background technique [0002] Malaria is a global insect-borne infectious disease caused by Plasmodium that seriously endangers human health. It is one of the three major infectious diseases together with tuberculosis and AIDS. According to the different types of Plasmodium, malaria is divided into Plasmodium vivax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale. Traditional means of combating falciparum malaria mainly rely on the prevention and treatment of antimalarial drugs, combined with sanitation measures such as insecticides and elimination of mosquito habitats to eliminate malaria-transmitting mosquito vectors. However, due to the gradual resistance of Plasmodium to antimalarial drugs and Anopheles mosquitoes to insecticides, the development of malaria vaccines is still the focus of curren...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/015A61P33/06
CPCY02A50/30
Inventor 徐文岳朱锋
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap